BLAINTRAVENOUSPOWDERPriority Review
Approved
Jun 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POLIVY (polatuzumab vedotin) is an antibody-drug conjugate (ADC) that combines an anti-CD79b monoclonal antibody with a microtubule-disrupting agent. It is approved for relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) in combination with bendamustine and rituximab. The drug delivers targeted cytotoxic payloads directly to lymphoma cells expressing CD79b.
$0.001BPart D
PeakProduct is at peak lifecycle stage with modest Part D utilization, suggesting established market presence with moderate commercial activity and specialized oncology field focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Started May 2026
30 enrolled
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaLymphoma+1 more
Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy
Started Dec 2025
200 enrolled
Diffuse Large B Cell Lymphoma (DLBCL)
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Started Jun 2025
38 enrolled
Diffuse Large B-Cell Lymphoma
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Started Apr 2025
594 enrolled
Lymphoma, Large B-Cell, Diffuse
A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma
Started Aug 2024
99 enrolled
Large B-cell Lymphoma
Worked on POLIVY at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.